Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.11604/pamj.supp.2020.35.24157 http://scihub22266oqcxt.onion/10.11604/pamj.supp.2020.35.24157 33623604!7875785!33623604     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 251.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pan+Afr+Med+J 2020 ; 35 (Suppl 2): 80 Nephropedia Template TP {{tp|p=33623604|t=2020. Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19 |pdf=|usr=}}{{33623604}} gab.com Text Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19 JO: Pan Afr Med J http://www.kidney.de/pget.php?&tw=1&pmid=33623604 #FOAvip As the novel coronavirus continues to spread globally and across Africa, efforts are being accelerated to identify effective preventive and therapeutic measures to mitigate its burden. Convalescent plasma and hyperimmune immunoglobulin are being considered as potential therapeutic options for the coronavirus disease 2019 (COVID-19). We highlight and contextualize the findings of a recent Cochrane rapid review that evaluated the effectiveness and safety of convalescent plasma or hyperimmune immunoglobulin transfusion in the treatment of people with COVID-19. From the eight studies it included, the review found limited and low-certainty evidence on the effectiveness and safety of convalescent plasma therapy in patients with COVID-19. The evidence was limited by the small number of participants and low-quality of included studies, as well as the inconsistency of outcome measures and reporting across studies. As African countries brace for the further spread of the virus, while exploring potential therapeutic options to mitigate its morbidity and mortality at peak, convalescent plasma transfusion may offer a therapeutic ray of hope for the continent. Considering the limited evidence of the effectiveness and safety in the treatment of COVID-19, it is imperative for this therapy to be investigated within African contexts to ascertain not only its effectiveness and safety, but also its practical implications within the capacity of national blood transfusion services and health systems in the region. Twit Text FOAVip Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19 ????Pan Afr Med J http://www.kidney.de/pget.php?&tw=1&pmid=33623604 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33623604 #FOAvip English Wikipedia <ref>{{Cite pmid|33623604}}</ref> Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19 #MMPMID33623604 Nnaji CA; Wiysonge CS Pan Afr Med J 2020[]; 35 (Suppl 2): 80 PMID33623604show ga As the novel coronavirus continues to spread globally and across Africa, efforts are being accelerated to identify effective preventive and therapeutic measures to mitigate its burden. Convalescent plasma and hyperimmune immunoglobulin are being considered as potential therapeutic options for the coronavirus disease 2019 (COVID-19). We highlight and contextualize the findings of a recent Cochrane rapid review that evaluated the effectiveness and safety of convalescent plasma or hyperimmune immunoglobulin transfusion in the treatment of people with COVID-19. From the eight studies it included, the review found limited and low-certainty evidence on the effectiveness and safety of convalescent plasma therapy in patients with COVID-19. The evidence was limited by the small number of participants and low-quality of included studies, as well as the inconsistency of outcome measures and reporting across studies. As African countries brace for the further spread of the virus, while exploring potential therapeutic options to mitigate its morbidity and mortality at peak, convalescent plasma transfusion may offer a therapeutic ray of hope for the continent. Considering the limited evidence of the effectiveness and safety in the treatment of COVID-19, it is imperative for this therapy to be investigated within African contexts to ascertain not only its effectiveness and safety, but also its practical implications within the capacity of national blood transfusion services and health systems in the region. |Africa/epidemiology[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/epidemiology/*therapy[MESH] |Humans[MESH]Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for(epmc).pdf DeepDyve Pubget Overpricing